Welcome to Idorsia

Idorsia announces
financial results for the
first half of 2020

Positive results in second
pivotal study with
daridorexant for
patients with
insomnia

Our 2019 report
consists of three
books

There’s more to Idorsia
than meets the eye!

Read the interview with
our CEO & CSO to get to
the bottom of the story...

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

02 Sep 2020	Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
02 Sep 2020	Idorsia assigns and transfers agreement with ReveraGen to Santhera
31 Aug 2020	Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States

Event	When
Nine-months 2020 Financial Results reporting*	October 22, 2020
Full-Year 2020 Financial Results reporting*	February 4, 2021
First Quarter 2021 Financial Results reporting	April 22, 2021

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:20:00 CET

24.98 CHF

+0.18 (+0.73 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland